Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

Background: Several trials have studied the role of unconventional fractionated radiotherapy in head and neck squamous cell carcinoma, but the effect of such treatment on survival is not clear. The aim of this meta-analysis was to assess whether this type of radiotherapy could improve survival.Metho...

Descripción completa

Detalles Bibliográficos
Publicado en:Lancet Vol. 368; no. 9538; pp. 843 - 855
Autores principales: Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot J, Le Maître A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LHJ, Fallai C, Fu KK, Sylvester R, Pignon J
Formato: research tables/charts Journal Article
Publicado: Lancet 9/2/2006
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106211522&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106211522
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01406736
        LAN
      jtl: Lancet
      issn: 01406736
      maglogo: N
    pubinfo:
      dt: 9/2/2006
      vid: 368
      iid: 9538
      pid: 1297
      pub: Lancet
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        106211522
        106211522
        NLM16950362
        2009294702
        10.1016/s0140-6736(06)69121-6
        NLM16950362
        106211522
      ppf: 843
      ppct: 12
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.
      aug:
        au:
          Bourhis J
          Overgaard J
          Audry H
          Ang KK
          Saunders M
          Bernier J
          Horiot J
          Le Maître A
          Pajak TF
          Poulsen MG
          O'Sullivan B
          Dobrowsky W
          Hliniak A
          Skladowski K
          Hay JH
          Pinto LHJ
          Fallai C
          Fu KK
          Sylvester R
          Pignon J
      sug:
        subj:
          Head and Neck Neoplasms Radiotherapy
          Aged
          Aged, 80 and Over
          Chi Square Test
          Embase
          Female
          Funding Source
          Log-Rank Test
          Male
          Medline
          Meta Analysis
          Middle Age
          Mortality
          Neoplasm Metastasis
          Radiotherapy Methods
          Survival
          Treatment Failure
          Treatment Outcomes
          Human
          Aged: 65+ years
          Aged, 80 & over
          Middle Aged: 45-64 years
          Female
          Male
      ab: Background: Several trials have studied the role of unconventional fractionated radiotherapy in head and neck squamous cell carcinoma, but the effect of such treatment on survival is not clear. The aim of this meta-analysis was to assess whether this type of radiotherapy could improve survival.Methods: Randomised trials comparing conventional radiotherapy with hyperfractionated or accelerated radiotherapy, or both, in patients with non-metastatic HNSCC were identified and updated individual patient data were obtained. Overall survival was the main endpoint. Trials were grouped in three pre-specified categories: hyperfractionated, accelerated, and accelerated with total dose reduction.Findings: 15 trials with 6515 patients were included. The median follow-up was 6 years. Tumours sites were mostly oropharynx and larynx; 5221 (74%) patients had stage III-IV disease (International Union Against Cancer, 1987). There was a significant survival benefit with altered fractionated radiotherapy, corresponding to an absolute benefit of 3.4% at 5 years (hazard ratio 0.92, 95% CI 0.86-0.97; p=0.003). The benefit was significantly higher with hyperfractionated radiotherapy (8% at 5 years) than with accelerated radiotherapy (2% with accelerated fractionation without total dose reduction and 1.7% with total dose reduction at 5 years, p=0.02). There was a benefit on locoregional control in favour of altered fractionation versus conventional radiotherapy (6.4% at 5 years; p<0.0001), which was particularly efficient in reducing local failure, whereas the benefit on nodal control was less pronounced. The benefit was significantly higher in the youngest patients (hazard ratio 0.78 [0.65-0.94] for under 50 year olds, 0.95 [0.83-1.09] for 51-60 year olds, 0.92 [0.81-1.06] for 61-70 year olds, and 1.08 [0.89-1.30] for over 70 year olds; test for trends p=0.007).Interpretation: Altered fractionated radiotherapy improves survival in patients with head and neck squamous cell carcinoma. Comparison of the different types of altered radiotherapy suggests that hyperfractionation has the greatest benefit.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N